The studied parameters and endpoints in these clinical trials were AKI, GFR, conventional as well as novel biomarkers of kidney function (e.g., urine NGAL/urine Cr and KIM-1), and electrolytes imbalances. This evidence concerns the gene HAVCR1 and acute kidney injury.